Search hospitals > Ohio > Zanesville
Genesis Healthcare System Cancer Care Center
Claim this profileZanesville, Ohio 43701
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
227 reported clinical trials
2 medical researchers
Summary
Genesis Healthcare System Cancer Care Center is a medical facility located in Zanesville, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Genesis Healthcare System Cancer Care Center is involved with conducting 227 clinical trials across 383 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
ER positive
HER2 negative
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
John P. KueblerStrecker Cancer Center-Belpre12 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Carcinoma
1 reported clinical trial
5 drugs studied
Clinical Trials running at Genesis Healthcare System Cancer Care Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Bladder Carcinoma
Melanoma
Cutaneous Melanoma
Bladder Cancer
Multiple Myeloma
Ovarian Cancer
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Genesis Healthcare System Cancer Care Center?
Genesis Healthcare System Cancer Care Center is a medical facility located in Zanesville, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Genesis Healthcare System Cancer Care Center is involved with conducting 227 clinical trials across 383 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and John P. Kuebler.